PRESS RELEASES

Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering

Josh Phillipson 2023-09-19 Josh Phillipson 2023-09-19

Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering

Read More

Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering

Josh Phillipson 2023-09-15 Josh Phillipson 2023-09-15

Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering

Read More

Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results

Josh Phillipson 2023-09-13 Josh Phillipson 2023-09-13

Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results

Read More

Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston

Josh Phillipson 2023-09-11 Josh Phillipson 2023-09-11

Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston

Read More

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

Josh Phillipson 2023-09-06 Josh Phillipson 2023-09-06

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

Scinai Immunotherapeutics

Read More

BiondVax Reports Second Quarter Financial Results and Provides Business Update

Guest User 2023-08-11 Guest User 2023-08-11

BiondVax Reports Second Quarter Financial Results and Provides Business Update

Read More

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

Guest User 2023-08-01 Guest User 2023-08-01

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

Read More

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

Guest User 2023-06-05 Guest User 2023-06-05

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

Read More

BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update

Guest User 2023-05-15 Guest User 2023-05-15

BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update

Read More

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

Guest User 2023-04-17 Guest User 2023-04-17

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

Read More

BiondVax to Present at BIO-Europe Spring

Guest User 2023-03-16 Guest User 2023-03-16

BiondVax to Present at BIO-Europe Spring

Read More

BiondVax Presenting at BIO CEO & Investor Conference

Guest User 2023-02-02 Guest User 2023-02-02

BiondVax Presenting at BIO CEO & Investor Conference

Read More

BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

Guest User 2023-01-23 Guest User 2023-01-23

BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

Read More

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

Guest User 2023-01-06 Guest User 2023-01-06

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

Read More

BiondVax to Present at Biotech Showcase 2023

Guest User 2023-01-05 Guest User 2023-01-05

BiondVax to Present at Biotech Showcase 2023

Read More